{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:47:49Z","timestamp":1763142469234,"version":"3.44.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,7]]},"DOI":"10.7759\/cureus.91775","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:27:51Z","timestamp":1757258871000},"source":"Crossref","is-referenced-by-count":1,"title":["Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Sharvani","family":"Alajpur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamer","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2023","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003645611","article-title":"Lenalidomide in multiple myeloma: current role and future directions","volume":"11","author":"Zeldis JB","year":"2010","unstructured":"Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP. Lenalidomide in multiple myeloma: current role and future directions. Expert Opin Pharmacother. 2010, 11:829-42. 10.1517\/14656561003645611","journal-title":"Expert Opin Pharmacother"},{"key":"ref3","unstructured":"Lenalidomide (Revlimid). risk of serious hepatic adverse drug reactions. (2013). Accessed: 2025: https:\/\/www.gov.uk\/drug-safety-update\/lenalidomide-revlimid-risk-of-serious-hepatic-adverse-drug-reactions."},{"article-title":"Lenalidomide","year":"2012","key":"ref4","unstructured":"Lenalidomide. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2012."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09940-9","article-title":"A proposed pathologic sub-classification of drug-induced liver injury","volume":"13","author":"Wang T","year":"2019","unstructured":"Wang T, Zhao X, Shao C, et al.. A proposed pathologic sub-classification of drug-induced liver injury. Hepatol Int. 2019, 13:339-51. 10.1007\/s12072-019-09940-9","journal-title":"Hepatol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102198","article-title":"Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone","volume":"47","author":"Filanovsky K","year":"2023","unstructured":"Filanovsky K, Temper N, Stanevsky A, Shvidel L. Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone. Clin Res Hepatol Gastroenterol. 2023, 47:102198. 10.1016\/j.clinre.2023.102198","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1732497","article-title":"Erratum to: drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics","volume":"41","author":"Bessone F","year":"2021","unstructured":"Bessone F, Hern\u00e1ndez N, Tanno M, Roma MG. Erratum to: drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021, 41:e1. 10.1055\/s-0041-1732497","journal-title":"Semin Liver Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28967","article-title":"Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements","volume":"65","author":"Bonkovsky HL","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, et al.. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017, 65:1267-77. 10.1002\/hep.28967","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"article-title":"Vanishing bile duct syndrome","year":"2012","key":"ref10","unstructured":"Vanishing bile duct syndrome. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2012."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388318-lenalidomide-associated-liver-injury-with-features-of-vanishing-bile-duct-syndrome-in-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:27:52Z","timestamp":1757258872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388318-lenalidomide-associated-liver-injury-with-features-of-vanishing-bile-duct-syndrome-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.91775","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,7]]}}}